












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































ATS bileaflet valve does not open to the full 85  it was
manufactured to attain, which may explain why the same
studies report that the valve closes extremely quickly [45].
This failure to open fully may also explain the reduced
closing noise reputed to be a feature of this valve. The
long-term effects of the suboptimal opening are not fully
understood [45].
Overall, at this early follow-up stage, the ATS open pivot
bileaflet valve has shown decreased levels of thrombosis and
hemolysis when compared to some earlier model valves.
There have been no structural changes reported, and reduced
transvalvular gradients have been measured [44].
FDA approval: The first clinical trial of the ATS valve
was in May of 1992, and the valve received FDA approval
in October 2000 [44].
4.2. The Edwards bileaflet valves
Models:E d w a r d s - D u r o m e d i c sv a l v e( d i s c o n t i n u e d )
(AKA TEKNA).
Type: Bileaflet valve.
Technical information: Introduced by Hemex Scientific in
1982 and subsequently acquired by Baxter Healthcare [46].
In 1988, Baxter Healthcare voluntarily withdrew the valve
(Fig. 10A) from the market citing 12 leaflet escapes out of a
total of 20,000 implants [47]. In June of 1990, the valve was
reintroduced to the market as the revised Edwards-Duro-
medics, and later still as the Edwards Tekna valve. These
valves are no longer on the market.
4.3. Edwards Mira (R) valve
The present Edwards Bileaflet valve is the Mira (R)
Valve (Fig. 10B). The mechanical components of the Mira
valve are manufactured by Sorin Biomedica (Italy). It differs
from the Sorin bileaflet Bicarbon in that the sewing ring is
softer and ‘‘waffled,’’ and has a Silicone insert. This makes
the cuff similar to the Starr-Edwards valve. This sewing cuff
is meant to increase the ease of implantation.
Sizerangeandavailabledimensions:Model3160inaortic
position: 19–27 mm. Model 9210 in mitral: 25–33 mm [48].
Physical characteristics: Central blood flow.
Fig. 10.
J. Butany et al. / Cardiovascular Pathology 12 (2003) 322–344 332
Potential complications:E a r l ym o d e l so ft h eS t a r r -
Edwards prostheses were reported to show poppet damage
(cracks) and occasionally embolization [10]. Thrombus
formation and pannus growth may occur at the base of the
struts and the apex of the closed cage, the latter potentially
leading to orifice stenosis and improper poppet seating with
resulting valvular incompetence [12]. Hemodynamic injury
to the aortic intima with subsequent thrombosis and fibrous
plaque formation to the endothelial lining can also occur,
especially at the proximal end of the ascending aorta [12].
Paravalvular leaks do occur, as does infective endocarditis
[13,14]. In valves made prior to 1966, the silastic poppet
often imbibed lipid and the dimension of the poppet
increased in comparison to the original specifications,
leading to a change in color and occasionally to ball
variance. This leads to decreased valve excursion, increased
valvular regurgitation [15] and, in some cases, even sudden
death [16]. Related to the high profile of this prosthesis, the
valve struts can get ‘‘trapped’’ in scar tissue on the left
ventricular free wall or on the inter ventricular septum.
(Most of these problems have largely been eliminated, but
may still occasionally be seen.)
Additional comments: Although chronologically a very
old valve, the Starr-Edwards caged ball prostheses was for
manyyearsthegoldstandardagainstwhichothervalveswere
compared. These valves have a longer history of clinical
usage than any other heart valve prosthesis [17]. Pathologists
may still observe these valves upon explantation.
FDA approval: Only models 1260 and 6120 are currently
approved in North America.
3. Single leaflet/tilting disc
3.1. The AorTech Ultracor mechanical valve
Model:A o r T e c hU l t r a c o rU 1 9 A – U 2 9 A( a o r t i c )a n d
U23M–U33M (mitral).
Fig. 1.
J. Butany et al. / Cardiovascular Pathology 12 (2003) 322–344 324
could be operated upon) has been reported in approximately
50% of patients with thrombosis of the tilting disc [10].
Perivalvular leak, not related to calcification, is reported
particularly with the aortic site valves and is apparently
greater in the 19-mm size [20]. Thrombus and tissue
overgrowth along the perimeter of the minor outflow region
can further reduce the flow in this region [21]. Pannus on
the sewing ring with extension onto the metal housing can
lead to valve dysfunction and predisposition to thrombosis
[20,22]. The incidence of infective endocarditis is similar to
that of all other MHVs.
Additional comments: The CC model was introduced to
reduce thrombosis originating in the small orifice. It
decreased the stagnation zone behind the disc and decreased
emboli from 4.2% to 1.2% per year after mitral valve
replacement (MVR) [23]. It was removed from the market
in 1986 after reports of a series of outlet strut fractures
leading to embolization of the disc. Close follow-up is
recommended for all patients. Prophylactic removal is
recommended in some patients with this series of valves,
especially those with valve sizes greater than 29 mm. Very
few if any more such cases have been reported in recent
years. Other factors considered are valve implant position,
weld date, welder identity, valve shop order, body surface
area and current age of patient [24,25].
FDA approval: Not approved by FDA (since 1986).
3.3. The Bjork-Shiley monostrut valve
Model:B j o r k - S h i l e yt i l t i n gd i s cw i t hs i n g l eo u t f l o w
strut (monostrut).
Type: Single leaflet, tilting disc.
Technical information:S h i l e yf i r s tm a n u f a c t u r e dt h e
Bjork-Shiley monostrut in 1981. Sorin Biomedica Cardio
bought it in 1992 from Pfizer and then sold it to Alliance
Medical Technologies.
Size range and available dimensions: This valve was
available in sewing ring sizes 17–33 mm with orifice
diameters of 12–24 mm (aortic and mitral valves).
Physical characteristics: The valve used a thin wafer
disk to pivot into open and closed position. The hinge
placement permitted a near central flow. The inlet strut
was C-shaped. The single outlet strut fit into the central
depression of the disc and held it in place.
Fig. 3.
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ring or cuff aimed at increasing the valve effective oriﬁce area 
and thus reducing the pressure gradient across the valve. Bile-
aﬂet valves are the most frequently used mechanical prostheses 
and account for more than 90% of mechanical valves implanted 
in the UK.
Implantation technique
A sewing cuff of a silastic ring clothed in Dacron™ is mounted 
onto  the  leaﬂet  and  housing  mechanism,  which  are  all  held 
within a mechanical ring. This sewing cuff permits the surgeon 
to place sutures that run from it to the patient’s native annulus. 
Recognition that a supra-annular implantation of the valve results 
in a larger oriﬁce area than the intra-annular position has led to 
changes in design and implantation techniques. These sutures 
are  either  non-absorbable  interrupted  Ethibond™  or  semi-
  continuous polypropylene spread closely and uniformly around 
the annulus. Accurate placement of these sutures is essential to 
prevent paraprosthetic leaks and potential failure.
Biological valves
These can be divided into stented and stentless bioprostheses.
Stented: these valves are most commonly harvested porcine aor-
tic valves or made of bovine or equine pericardium (Figure 3). 
The heterograft valve tissue is preserved in glutaraldehyde using 
various techniques. Advances in tissue ﬁxation techniques over 
the years have signiﬁcantly reduced the antigenicity and rates of 
calciﬁcation thus improving long-term outcomes. Durability is 
now much improved and when implanted in the conventional 
age groups these valves demonstrate good function for up to 12 
years and beyond. The ﬁrst heart valves that were implanted 
often failed for operative technical reasons. Surgical implanta-
tion was simply too difﬁcult. As a solution to this, the biological 
valves were mounted on a sewing ring that supported the valve 
structurally.  These  stented  valves  have  become  the  mainstay 
of bioprosthetic implantation, but haemodynamic and durabil-
ity issues have led to the continued development of stentless 
valves.
Stentless: these are implanted primarily in the aortic position. 
Repeated attempts to implant valves in the mitral position have 
been largely unsuccessful. They are implanted directly onto the 
native valvular annulus without the use of a rigid sewing cuff and 
require a more complex surgical technique. These valves include:
  •    autografts (from the same individual, e.g. pulmonary to aortic)
  •   homograft (from a different individual, e.g. cadaveric)
  •   hetero- or xenograft (from a different species, e.g. porcine) 
(Figure 4).
They have several theoretical advantages. These valves avoid 
the need of a rigid sewing ring and thus:
  •    increases the effective oriﬁce area thereby reducing the trans-
valvular gradient
  •    provides the closest anatomical and haemodynamic proﬁle to 
native valves
  •    may  have  slower  degeneration  rates  compared  to  stented 
counterparts,  by  maintaining  the  conditions  of  the  native 
  aortic root and including the native sinuses.
Surgical techniques
Stented valves are implanted with exactly the same techniques as 
used for the implantation of mechanical valves. Stentless valves, 
in contrast, are implanted using two suture lines: a proximal one 
to the annulus and a more distal one to the ascending aorta. The 
second suture line requires accurate spatial distribution of the 
three commissures that support the three leaﬂets to avoid para-
prosthetic leak and increased transvalvular gradient, and to ensure 
good opening and closing function and increased durability.
The procedure is therefore longer and more challenging.
In certain circumstances, the homograft or the stentless het-
erograft can be implanted as a valve root complex with proximal 
and distal suture lines. In this situation the operative technique 
Figure 2 Medtronic Hall™ tilting-disc valve.
Figure 3 Carpentier–Edwards Perimount™ pericardial aortic 
bioprosthesis.
Figure 4 Edwards Prima Plus™ stentless aortic bioprosthesis.
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and thus reducing the pressure gradient across the valve. Bile-
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in the UK.
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to place sutures that run from it to the patient’s native annulus. 
Recognition that a supra-annular implantation of the valve results 
in a larger oriﬁce area than the intra-annular position has led to 
changes in design and implantation techniques. These sutures 
are  either  non-absorbable  interrupted  Ethibond™  or  semi-
  continuous polypropylene spread closely and uniformly around 
the annulus. Accurate placement of these sutures is essential to 
prevent paraprosthetic leaks and potential failure.
Biological valves
These can be divided into stented and stentless bioprostheses.
Stented: these valves are most commonly harvested porcine aor-
tic valves or made of bovine or equine pericardium (Figure 3). 
The heterograft valve tissue is preserved in glutaraldehyde using 
various techniques. Advances in tissue ﬁxation techniques over 
the years have signiﬁcantly reduced the antigenicity and rates of 
calciﬁcation thus improving long-term outcomes. Durability is 
now much improved and when implanted in the conventional 
age groups these valves demonstrate good function for up to 12 
years and beyond. The ﬁrst heart valves that were implanted 
often failed for operative technical reasons. Surgical implanta-
tion was simply too difﬁcult. As a solution to this, the biological 
valves were mounted on a sewing ring that supported the valve 
structurally.  These  stented  valves  have  become  the  mainstay 
of bioprosthetic implantation, but haemodynamic and durabil-
ity issues have led to the continued development of stentless 
valves.
Stentless: these are implanted primarily in the aortic position. 
Repeated attempts to implant valves in the mitral position have 
been largely unsuccessful. They are implanted directly onto the 
native valvular annulus without the use of a rigid sewing cuff and 
require a more complex surgical technique. These valves include:
  •    autografts (from the same individual, e.g. pulmonary to aortic)
  •   homograft (from a different individual, e.g. cadaveric)
  •   hetero- or xenograft (from a different species, e.g. porcine) 
(Figure 4).
They have several theoretical advantages. These valves avoid 
the need of a rigid sewing ring and thus:
  •    increases the effective oriﬁce area thereby reducing the trans-
valvular gradient
  •    provides the closest anatomical and haemodynamic proﬁle to 
native valves
  •    may  have  slower  degeneration  rates  compared  to  stented 
counterparts,  by  maintaining  the  conditions  of  the  native 
  aortic root and including the native sinuses.
Surgical techniques
Stented valves are implanted with exactly the same techniques as 
used for the implantation of mechanical valves. Stentless valves, 
in contrast, are implanted using two suture lines: a proximal one 
to the annulus and a more distal one to the ascending aorta. The 
second suture line requires accurate spatial distribution of the 
three commissures that support the three leaﬂets to avoid para-
prosthetic leak and increased transvalvular gradient, and to ensure 
good opening and closing function and increased durability.
The procedure is therefore longer and more challenging.
In certain circumstances, the homograft or the stentless het-
erograft can be implanted as a valve root complex with proximal 
and distal suture lines. In this situation the operative technique 
Figure 2 Medtronic Hall™ tilting-disc valve.
Figure 3 Carpentier–Edwards Perimount™ pericardial aortic 
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Percutaneous aortic valve replacement   M
Medical Illustrator: Joseph Pangrace




The catheter is advanced via the femoral 
vein, traversing the interatrial septum and 
the mitral valve, and is positioned within 
the diseased aortic valve.
Advantages
Femoral vein accommodates the large 
  catheter sheath
Easy management of peripheral access 
  site
Disadvantages
Risk of mitral valve injury and severe 
  mitral valve regurgitation
Correctly positioning the prosthetic valve 
  can be challenging
This technique is no longer in use.
Retrograde or transfemoral technique 
The catheter is advanced to the stenotic 
aortic valve via the femoral artery.
Advantages
Faster, technically easier than antegrade 
  approach
Disadvantages
Potential for injury to the aortofemoral 
  vessels
Crossing the stenotic aortic valve can be 
  challenging
Transapical technique 
A valve delivery system is inserted via a small intercostal incision. 
The apex of the left ventricle is punctured, and the prosthetic valve is 
positioned within the stenotic aortic valve.
   Advantages
   Access to the stenotic valve is more direct
   Avoids potential complications of a large peripheral access site
   Disadvantages
   Potential for complications related to puncture of the left ventricle
   Requires general anesthesia and chest tubes
The aortic valve prosthesis is placed at mid-position in the patient’s aortic valve so as not to im-
pinge on the coronary ostia or to impede the motion of the anterior mitral leaﬂet (a). The prosthesis 
is deployed by inﬂating (b), rapidly deﬂating, and quickly withdrawing the delivery balloon (c).
Percutaneous aortic valve replacement is done via a retrograde, antegrade, or transapical approach. Each has its 
challenges. In all three approaches, the positioning of the prosthetic valve is determined by the patient’s native 
valvular structure and anatomy and is guided by ﬂuoroscopic imaging, supra-aortic angiography, and transesophageal 
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COL mg in 6 ml  Area picco 
0  35557 
0,02  318038 
0,05  566416 
0,16  2008163 
0,24  2946444 
0,3  3411636 





































































































































































































































TDOC mg in 6ml  Area picco 
0  187978 
0,02  5647484 
0,04  11096691 
0,1  29018398 
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 ﾠ con	
 ﾠ un	
 ﾠ R2=0,98215	
 ﾠ utilizzando	
 ﾠ un	
 ﾠ
campione	
 ﾠdi	
 ﾠpeso	
 ﾠ195,00	
 ﾠmg	
 ﾠe	
 ﾠcon	
 ﾠil	
 ﾠgradiente	
 ﾠindicato	
 ﾠin	
 ﾠMateriali	
 ﾠe	
 ﾠMetodi.	
 ﾠ
	
 ﾠ
4.3	
 ﾠDeterminazione	
 ﾠdelle	
 ﾠquantità	
 ﾠ
Le	
 ﾠquantità	
 ﾠdi	
 ﾠdetergente	
 ﾠall’interno	
 ﾠdei	
 ﾠcampioni	
 ﾠanalizzati	
 ﾠè	
 ﾠstato	
 ﾠricavato	
 ﾠinserendo	
 ﾠal	
 ﾠ
posto	
 ﾠ della	
 ﾠ variabile	
 ﾠ y	
 ﾠ il	
 ﾠ dato	
 ﾠ relativo	
 ﾠ all’area	
 ﾠ dell’analita	
 ﾠ e	
 ﾠ ricavando	
 ﾠ l’incognita	
 ﾠ x.	
 ﾠ
Essendo	
 ﾠstati	
 ﾠusati	
 ﾠlembi	
 ﾠdi	
 ﾠpesi	
 ﾠdifferenti	
 ﾠper	
 ﾠla	
 ﾠretta	
 ﾠdi	
 ﾠtaratura	
 ﾠe	
 ﾠper	
 ﾠi	
 ﾠcampioni	
 ﾠè	
 ﾠstato	
 ﾠ
necessario	
 ﾠin	
 ﾠprimo	
 ﾠluogo	
 ﾠmodificare	
 ﾠla	
 ﾠretta.	
 ﾠL’intercetta	
 ﾠdelle	
 ﾠnostre	
 ﾠrette	
 ﾠcorrisponde	
 ﾠ
al	
 ﾠvalore	
 ﾠdi	
 ﾠpicco	
 ﾠdel	
 ﾠcromatogramma	
 ﾠbianco	
 ﾠovvero	
 ﾠsenza	
 ﾠdetergente.	
 ﾠEssendo	
 ﾠi	
 ﾠvalori	
 ﾠ
dei	
 ﾠpicchi	
 ﾠproporzionali	
 ﾠalla	
 ﾠquantità	
 ﾠanalizzata,	
 ﾠda	
 ﾠpesi	
 ﾠdiversi	
 ﾠdel	
 ﾠmedesimo	
 ﾠcampione	
 ﾠ
risulterebbero	
 ﾠ cromatogrammi	
 ﾠ differenti.	
 ﾠ Per	
 ﾠ questo	
 ﾠ motivo	
 ﾠ con	
 ﾠ una	
 ﾠ proporzione	
 ﾠ
otteniamo	
 ﾠil	
 ﾠnuovo	
 ﾠvalore	
 ﾠdell’intercetta	
 ﾠpesando	
 ﾠcosì	
 ﾠla	
 ﾠretta	
 ﾠsulla	
 ﾠmassa	
 ﾠdei	
 ﾠcampioni	
 ﾠ
analizzati.	
 ﾠ Ciò	
 ﾠ che	
 ﾠ rimane	
 ﾠ immutato	
 ﾠ è	
 ﾠ chiaramente	
 ﾠ la	
 ﾠ derivata	
 ﾠ della	
 ﾠ retta	
 ﾠ che	
 ﾠ resta	
 ﾠ
costante.	
 ﾠ In	
 ﾠ tabella	
 ﾠ 4.5	
 ﾠ sono	
 ﾠ mostrati	
 ﾠ i	
 ﾠ valori	
 ﾠ di	
 ﾠ peso	
 ﾠ dei	
 ﾠ campioni	
 ﾠ e	
 ﾠ delle	
 ﾠ nuove	
 ﾠ
intercette.	
 ﾠ
y	
 ﾠ=	
 ﾠ128586x	
 ﾠ+	
 ﾠ110604	
 ﾠ
R²	
 ﾠ=	
 ﾠ0,98215	
 ﾠ
0	
 ﾠ
100000	
 ﾠ
200000	
 ﾠ
300000	
 ﾠ
400000	
 ﾠ
500000	
 ﾠ
600000	
 ﾠ
700000	
 ﾠ
800000	
 ﾠ
900000	
 ﾠ
1000000	
 ﾠ
0	
 ﾠ 1	
 ﾠ 2	
 ﾠ 3	
 ﾠ 4	
 ﾠ 5	
 ﾠ 6	
 ﾠ 7	
 ﾠ
A
r
e
a
	
 ﾠ
p
i
c
c
o
	
 ﾠ
μg	
 ﾠSDS	
 ﾠ	
 ﾠ
	
 ﾠ 48	
 ﾠ
Tabella	
 ﾠ4.5:	
 ﾠNuove	
 ﾠintercette	
 ﾠdelle	
 ﾠrette	
 ﾠdi	
 ﾠtaratura	
 ﾠ
Metodo	
 ﾠ
(Detergente)	
 ﾠ
Peso	
 ﾠ
delipidizzato	
 ﾠ
retta	
 ﾠ(mg)	
 ﾠ
Intercetta	
 ﾠ
originale	
 ﾠ
Peso	
 ﾠ
Campione	
 ﾠ
(mg)	
 ﾠ
Intercetta	
 ﾠ
nuova	
 ﾠ
Dohmen	
 ﾠ(DOC)	
 ﾠ 187,00	
 ﾠ 270943,00	
 ﾠ 193,00	
 ﾠ 279636,40	
 ﾠ
Haverich	
 ﾠ(DOC)	
 ﾠ 187,00	
 ﾠ 270943,00	
 ﾠ 173,85	
 ﾠ 251890,00	
 ﾠ
Haverich	
 ﾠ(SDS)	
 ﾠ 195,00	
 ﾠ 110604,00	
 ﾠ 173,85	
 ﾠ 98607,72	
 ﾠ
TRICOL	
 ﾠ(COL)	
 ﾠ 235,91	
 ﾠ 123376,00	
 ﾠ 213,22	
 ﾠ 111509,60	
 ﾠ
TRITDOC	
 ﾠ(TDOC)	
 ﾠ 235,91	
 ﾠ 80789,00	
 ﾠ 177,46	
 ﾠ 60772,39	
 ﾠ
	
 ﾠ
Saranno	
 ﾠora	
 ﾠinvece	
 ﾠriportati	
 ﾠi	
 ﾠrisultati	
 ﾠottenuti	
 ﾠdall’estrapolazione,	
 ﾠdapprima	
 ﾠil	
 ﾠvalore	
 ﾠdi	
 ﾠ
peso	
 ﾠdi	
 ﾠdetergente	
 ﾠin	
 ﾠmg	
 ﾠper	
 ﾠ6ml	
 ﾠdi	
 ﾠsoluzione,	
 ﾠpoi	
 ﾠper	
 ﾠ100ml	
 ﾠdi	
 ﾠsoluzione	
 ﾠe	
 ﾠinfine	
 ﾠverrà	
 ﾠ
riportato	
 ﾠil	
 ﾠvalore	
 ﾠdi	
 ﾠdetergente	
 ﾠnormalizzato	
 ﾠal	
 ﾠvalore	
 ﾠdel	
 ﾠpeso	
 ﾠdel	
 ﾠcampione.	
 ﾠ
Area	
 ﾠPicco	
 ﾠ mg	
 ﾠin	
 ﾠ6mL	
 ﾠ mg	
 ﾠin	
 ﾠ100mL	
 ﾠ mg	
 ﾠdet/mg	
 ﾠ
campione	
 ﾠ
164645	
 ﾠ 0,00531354	
 ﾠ 0,088559	
 ﾠ 4,15341e-ﾭ‐04	
 ﾠ
161732	
 ﾠ 0,00502224	
 ﾠ 0,083704	
 ﾠ 3,92571e-ﾭ‐04	
 ﾠ
157251	
 ﾠ 0,00457414	
 ﾠ 0,076235	
 ﾠ 3,57545e-ﾭ‐04	
 ﾠ
Tabella	
 ﾠ4.6:	
 ﾠRisultati	
 ﾠdell’analisi	
 ﾠquantitative	
 ﾠdi	
 ﾠresidui	
 ﾠdi	
 ﾠCOL	
 ﾠnei	
 ﾠcampioni	
 ﾠdelipidizzati	
 ﾠcon	
 ﾠmetodo	
 ﾠTRICOL	
 ﾠ
	
 ﾠ
Area	
 ﾠPicco	
 ﾠ mg	
 ﾠin	
 ﾠ6mL	
 ﾠ mg	
 ﾠin	
 ﾠ100mL	
 ﾠ mg	
 ﾠdet/mg	
 ﾠ
campione	
 ﾠ
354585	
 ﾠ 0,000979375	
 ﾠ 0,016322922	
 ﾠ 9,19809e-ﾭ‐05	
 ﾠ
361767	
 ﾠ 0,001003315	
 ﾠ 0,016721922	
 ﾠ 9,42292e-ﾭ‐05	
 ﾠ
366693	
 ﾠ 0,001019735	
 ﾠ 0,016995589	
 ﾠ 9,57714e-ﾭ‐05	
 ﾠ
Tabella	
 ﾠ4.7:	
 ﾠRisultati	
 ﾠdell’analisi	
 ﾠquantitative	
 ﾠdi	
 ﾠresidui	
 ﾠdi	
 ﾠTDOC	
 ﾠnei	
 ﾠcampioni	
 ﾠdelipidizzati	
 ﾠcon	
 ﾠmetodo	
 ﾠTRITDOC	
 ﾠ
	
 ﾠ
Area	
 ﾠPicco	
 ﾠ mg	
 ﾠin	
 ﾠ6mL	
 ﾠ mg	
 ﾠin	
 ﾠ100mL	
 ﾠ mg	
 ﾠdet/mg	
 ﾠ
campione	
 ﾠ
368216	
 ﾠ 0,012654229	
 ﾠ 0,21090381	
 ﾠ 1,092766e-ﾭ‐03	
 ﾠ
376160	
 ﾠ 0,013789086	
 ﾠ 0,22981809	
 ﾠ 1,190767e-ﾭ‐03	
 ﾠ
369205	
 ﾠ 0,012795514	
 ﾠ 0,21325857	
 ﾠ 1,104967e-ﾭ‐03	
 ﾠ
Tabella	
 ﾠ4.8:	
 ﾠRisultati	
 ﾠdell’analisi	
 ﾠquantitative	
 ﾠdi	
 ﾠresidui	
 ﾠdi	
 ﾠDOC	
 ﾠnei	
 ﾠcampioni	
 ﾠdelipidizzati	
 ﾠcon	
 ﾠmetodo	
 ﾠDohmen	
 ﾠ
	
 ﾠ
Area	
 ﾠPicco	
 ﾠ mg	
 ﾠin	
 ﾠ6mL	
 ﾠ mg	
 ﾠin	
 ﾠ100mL	
 ﾠ mg	
 ﾠdet/mg	
 ﾠ
campione	
 ﾠ
314417	
 ﾠ 0,008932429	
 ﾠ 0,14887381	
 ﾠ 8,56335e-ﾭ‐04	
 ﾠ
329557	
 ﾠ 0,011095286	
 ﾠ 0,18492142	
 ﾠ 10,6368e-ﾭ‐04	
 ﾠ
312398	
 ﾠ 0,008644765	
 ﾠ 0,14406667	
 ﾠ 8,28684e-ﾭ‐04	
 ﾠ
Tabella	
 ﾠ4.9:	
 ﾠRisultati	
 ﾠdell’analisi	
 ﾠquantitative	
 ﾠdi	
 ﾠresidui	
 ﾠdi	
 ﾠDOC	
 ﾠnei	
 ﾠcampioni	
 ﾠdelipidizzati	
 ﾠcon	
 ﾠmetodo	
 ﾠHaverich	
 ﾠ
	
 ﾠ
Area	
 ﾠPicco	
 ﾠ μg	
 ﾠin	
 ﾠ9mL	
 ﾠ μg	
 ﾠin	
 ﾠ100mL	
 ﾠ μg	
 ﾠdet/μg	
 ﾠ
campione	
 ﾠ
203910	
 ﾠ 0,818924922	
 ﾠ 9,099165798	
 ﾠ 5,23392e-ﾭ‐05	
 ﾠ
180822	
 ﾠ 0,639371938	
 ﾠ 7,104132643	
 ﾠ 4,08636e-ﾭ‐05	
 ﾠ
164221	
 ﾠ 0,510267681	
 ﾠ 5,669640897	
 ﾠ 3,26123e-ﾭ‐05	
 ﾠ
Tabella	
 ﾠ4.10:	
 ﾠRisultati	
 ﾠdell’analisi	
 ﾠquantitative	
 ﾠdi	
 ﾠresidui	
 ﾠdi	
 ﾠSDS	
 ﾠnei	
 ﾠcampioni	
 ﾠdelipidizzati	
 ﾠcon	
 ﾠmetodo	
 ﾠHaverich	
 ﾠ
	
 ﾠ
	
 ﾠ	
 ﾠ
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 ﾠ
Il	
 ﾠcalcolo	
 ﾠdelle	
 ﾠmedie	
 ﾠe	
 ﾠdelle	
 ﾠdeviazioni	
 ﾠstandard	
 ﾠfornisce	
 ﾠi	
 ﾠseguenti	
 ﾠrisultati	
 ﾠ
	
 ﾠ
Tabella	
 ﾠ4.11:	
 ﾠRisultati	
 ﾠforniti	
 ﾠdal	
 ﾠmetodo	
 ﾠdella	
 ﾠregressione	
 ﾠlineare	
 ﾠcon	
 ﾠrispettive	
 ﾠdeviazioni	
 ﾠstandard	
 ﾠ	
 ﾠ
	
 ﾠ
	
 ﾠ
Figura	
 ﾠ4.16:	
 ﾠValori	
 ﾠdi	
 ﾠμg	
 ﾠdetergente/mg	
 ﾠcampione	
 ﾠumido	
 ﾠ
	
 ﾠ
Esprimendo	
 ﾠi	
 ﾠrisultati	
 ﾠnel	
 ﾠrapporto	
 ﾠ(mg	
 ﾠdetergente/mg	
 ﾠcampione	
 ﾠsecco)%	
 ﾠsi	
 ﾠottiene	
 ﾠ
	
 ﾠ
	
 ﾠ
Tabella	
 ﾠ4.12:	
 ﾠRisultati	
 ﾠdei	
 ﾠquantitativi	
 ﾠdi	
 ﾠdetergenti	
 ﾠresidui	
 ﾠespressi	
 ﾠin	
 ﾠ%	
 ﾠdel	
 ﾠrapporto	
 ﾠmg	
 ﾠdetergente/mg	
 ﾠcampione	
 ﾠ
secco	
 ﾠ
Metodo	
 ﾠ(Detergente)	
 ﾠ %	
 ﾠdetergente	
 ﾠrispetto	
 ﾠal	
 ﾠ
campione	
 ﾠsecco	
 ﾠ
Deviazione	
 ﾠstandard	
 ﾠsul	
 ﾠ
valore	
 ﾠpercentuale	
 ﾠ
Dohmen	
 ﾠ(DOC)	
 ﾠ 1,13	
 ﾠ 0,053	
 ﾠ
Haverich	
 ﾠ(DOC)	
 ﾠ 0,916	
 ﾠ 0,12	
 ﾠ
Haverich	
 ﾠ(SDS)	
 ﾠ 0,0419	
 ﾠ 0,009	
 ﾠ
TRICOL	
 ﾠ(COL)	
 ﾠ 0,388	
 ﾠ 0,029	
 ﾠ
TRITDOC	
 ﾠ(TDOC)	
 ﾠ 0,0939	
 ﾠ 0,0019	
 ﾠ
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Dohmen	
 ﾠ(DOC)	
 ﾠ Haverich	
 ﾠ(DOC)	
 ﾠ TRICOL	
 ﾠ(COL)	
 ﾠ TRITDOC	
 ﾠ(TDOC)	
 ﾠ Haverich	
 ﾠ(SDS)	
 ﾠ
Metodo	
 ﾠ
(Detergente)	
 ﾠ
Media	
 ﾠ(μg	
 ﾠdetergente/mg	
 ﾠ
campione	
 ﾠumido)	
 ﾠ
Media	
 ﾠ(μmol	
 ﾠ
detergente/mg	
 ﾠ
campione	
 ﾠumido)	
 ﾠ
Deviazione	
 ﾠ
standard	
 ﾠ(μg	
 ﾠ
detergente/mg	
 ﾠ
campione	
 ﾠumido)	
 ﾠ
Dohmen	
 ﾠ(DOC)	
 ﾠ 1,1295437	
 ﾠ 0,002737909	
 ﾠ 0,053408	
 ﾠ
Haverich	
 ﾠ(DOC)	
 ﾠ 0,9162348	
 ﾠ 0,002209625	
 ﾠ 0,128441	
 ﾠ
Haverich	
 ﾠ(SDS)	
 ﾠ 0,0419383	
 ﾠ 0,000145641	
 ﾠ 0,009907	
 ﾠ
TRICOL	
 ﾠ(COL)	
 ﾠ	
 ﾠ 0,3884865	
 ﾠ 0,000901173	
 ﾠ 0,029114	
 ﾠ
TRITDOC	
 ﾠ(TDOC)	
 ﾠ 0,0939938	
 ﾠ 0,000180184	
 ﾠ 0,001906	
 ﾠ	
 ﾠ
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4.4	
 ﾠDiscussione	
 ﾠ
I	
 ﾠdati	
 ﾠriportati	
 ﾠin	
 ﾠfig.	
 ﾠ4.16	
 ﾠdimostrano	
 ﾠche	
 ﾠle	
 ﾠquantità	
 ﾠdi	
 ﾠdetergente	
 ﾠresiduo	
 ﾠper	
 ﾠquantità	
 ﾠ
di	
 ﾠcampione	
 ﾠumido	
 ﾠsono	
 ﾠdiverse	
 ﾠal	
 ﾠvariare	
 ﾠdel	
 ﾠmetodo	
 ﾠdi	
 ﾠdecellularizzazione.	
 ﾠ	
 ﾠ
Essendo	
 ﾠ i	
 ﾠ campioni	
 ﾠ di	
 ﾠ lembi	
 ﾠ aortici	
 ﾠ molto	
 ﾠ differenti	
 ﾠ è	
 ﾠ stato	
 ﾠ necessario	
 ﾠ esprimere	
 ﾠ le	
 ﾠ
quantità	
 ﾠ di	
 ﾠ detergenti	
 ﾠ in	
 ﾠ rapporto	
 ﾠ al	
 ﾠ peso	
 ﾠ del	
 ﾠ campione,	
 ﾠ ottenendo	
 ﾠ così	
 ﾠ dei	
 ﾠ valori	
 ﾠ
confrontabili.	
 ﾠ
La	
 ﾠpossibilità	
 ﾠdi	
 ﾠanalizzare	
 ﾠin	
 ﾠmaniera	
 ﾠdiretta	
 ﾠle	
 ﾠquantità	
 ﾠdi	
 ﾠdetergenti	
 ﾠresidue	
 ﾠmostra	
 ﾠ
come	
 ﾠi	
 ﾠdetergenti	
 ﾠnon	
 ﾠvengano	
 ﾠcompletamente	
 ﾠrimossi	
 ﾠdalle	
 ﾠmatrici	
 ﾠcome	
 ﾠipotizzato	
 ﾠda	
 ﾠ
studi	
 ﾠ precedentemente	
 ﾠ pubblicati[32,34,35].	
 ﾠ La	
 ﾠ quantificazione	
 ﾠ dei	
 ﾠ detergenti	
 ﾠ nei	
 ﾠ
lavaggi	
 ﾠinseriti	
 ﾠnei	
 ﾠmetodi	
 ﾠdi	
 ﾠdecellularizzazione	
 ﾠnon	
 ﾠsono	
 ﾠuno	
 ﾠstrumento	
 ﾠpreciso	
 ﾠper	
 ﾠ
verificare	
 ﾠla	
 ﾠpresenza	
 ﾠo	
 ﾠmeno	
 ﾠdi	
 ﾠquantità	
 ﾠdi	
 ﾠdetergenti	
 ﾠche	
 ﾠpossono	
 ﾠessere	
 ﾠdannose.	
 ﾠLo	
 ﾠ
sviluppo	
 ﾠdel	
 ﾠmetodo	
 ﾠci	
 ﾠha	
 ﾠpermesso,	
 ﾠdi	
 ﾠverificare	
 ﾠla	
 ﾠpresenza	
 ﾠpotenzialmente	
 ﾠdannosa,	
 ﾠ
di	
 ﾠsostanze	
 ﾠcitotossiche	
 ﾠnelle	
 ﾠstrutture	
 ﾠdella	
 ﾠmatrice	
 ﾠextracellulare.	
 ﾠAnche	
 ﾠse	
 ﾠle	
 ﾠquantità	
 ﾠ
rilevate	
 ﾠdal	
 ﾠnostro	
 ﾠmetodo	
 ﾠsono	
 ﾠuna	
 ﾠminima	
 ﾠparte	
 ﾠdel	
 ﾠdetergente	
 ﾠutilizzato	
 ﾠnei	
 ﾠmetodi	
 ﾠ
di	
 ﾠdecellularizzazione	
 ﾠla	
 ﾠloro	
 ﾠpresenza	
 ﾠè	
 ﾠdimostrata	
 ﾠdal	
 ﾠmetodo	
 ﾠcromatografico	
 ﾠe	
 ﾠdalle	
 ﾠ
analisi	
 ﾠdi	
 ﾠmassa.	
 ﾠ
Per	
 ﾠquanto	
 ﾠriguarda	
 ﾠi	
 ﾠdetergenti	
 ﾠresidui	
 ﾠil	
 ﾠmetodo	
 ﾠDohmen	
 ﾠrisultata	
 ﾠil	
 ﾠpeggiore	
 ﾠtra	
 ﾠi	
 ﾠ
quattro	
 ﾠmetodi	
 ﾠanalizzati,	
 ﾠla	
 ﾠquantità	
 ﾠdi	
 ﾠDOC	
 ﾠche	
 ﾠesso	
 ﾠlascia	
 ﾠnei	
 ﾠtessuti	
 ﾠrisulta	
 ﾠdi	
 ﾠcirca	
 ﾠ
una	
 ﾠparte	
 ﾠsu	
 ﾠmille	
 ﾠdel	
 ﾠcampione	
 ﾠtotale.	
 ﾠLa	
 ﾠpresenza	
 ﾠdi	
 ﾠun	
 ﾠcosì	
 ﾠelevato	
 ﾠquantitativo	
 ﾠdel	
 ﾠ
detergente	
 ﾠionico	
 ﾠè	
 ﾠdannoso	
 ﾠsia	
 ﾠper	
 ﾠil	
 ﾠrischio	
 ﾠdi	
 ﾠcalcificazione	
 ﾠsia	
 ﾠper	
 ﾠquanto	
 ﾠriguarda	
 ﾠ
l’inibizione	
 ﾠdel	
 ﾠprocesso	
 ﾠdi	
 ﾠripopolazione	
 ﾠdella	
 ﾠvalvola[18,21].	
 ﾠ	
 ﾠ
Il	
 ﾠmetodo	
 ﾠHaverich	
 ﾠrisulta	
 ﾠleggermente	
 ﾠmigliore	
 ﾠper	
 ﾠquanto	
 ﾠconcerne	
 ﾠi	
 ﾠresidui	
 ﾠdi	
 ﾠDOC,	
 ﾠ
ma	
 ﾠelimina	
 ﾠcon	
 ﾠi	
 ﾠlavaggi	
 ﾠgran	
 ﾠparte	
 ﾠdell’altro	
 ﾠdetergente	
 ﾠionico	
 ﾠutilizzato	
 ﾠovvero	
 ﾠil	
 ﾠSDS;	
 ﾠ
la	
 ﾠpresenza	
 ﾠsimultanea	
 ﾠdei	
 ﾠdue	
 ﾠgarantisce	
 ﾠun	
 ﾠeffetto	
 ﾠdi	
 ﾠmutua	
 ﾠeliminazione	
 ﾠche	
 ﾠtuttavia,	
 ﾠ
in	
 ﾠgenerale,	
 ﾠnon	
 ﾠraggiunge	
 ﾠlivelli	
 ﾠsoddisfacenti	
 ﾠdi	
 ﾠquantità	
 ﾠresidue	
 ﾠrispetto	
 ﾠal	
 ﾠcampione	
 ﾠ
totale.	
 ﾠ	
 ﾠ
Il	
 ﾠmetodo	
 ﾠTRICOL	
 ﾠraggiunge	
 ﾠrisultati	
 ﾠmigliori	
 ﾠrispetto	
 ﾠai	
 ﾠprecedenti	
 ﾠdue	
 ﾠmetodi.	
 ﾠCiò	
 ﾠpuò	
 ﾠ
essere	
 ﾠ dovuto	
 ﾠ a	
 ﾠ diversi	
 ﾠ fattori.	
 ﾠ La	
 ﾠ presenza	
 ﾠ di	
 ﾠ due	
 ﾠ detergenti	
 ﾠ (Triton	
 ﾠ X-ﾭ‐100	
 ﾠ e	
 ﾠ COL)	
 ﾠ
garantisce	
 ﾠ gli	
 ﾠ stessi	
 ﾠ effetti	
 ﾠ ottenuti	
 ﾠ da	
 ﾠ Haverich,	
 ﾠ anche	
 ﾠ se	
 ﾠ la	
 ﾠ quantità	
 ﾠ di	
 ﾠ detergente	
 ﾠ
utilizzata	
 ﾠ in	
 ﾠ proporzione	
 ﾠ è	
 ﾠ maggiore.	
 ﾠ La	
 ﾠ presenza	
 ﾠ di	
 ﾠ un	
 ﾠ detergente	
 ﾠ non	
 ﾠ ionico,	
 ﾠ più	
 ﾠ
facilmente	
 ﾠlavabile,	
 ﾠimplica	
 ﾠnon	
 ﾠsolo	
 ﾠl’utilizzo	
 ﾠdi	
 ﾠminori	
 ﾠquantità	
 ﾠdi	
 ﾠCOL	
 ﾠcon	
 ﾠconseguente	
 ﾠ
diminuzione	
 ﾠdi	
 ﾠquantità	
 ﾠresidue,	
 ﾠma	
 ﾠanche	
 ﾠuna	
 ﾠmaggior	
 ﾠpreservazione	
 ﾠdella	
 ﾠmatrice	
 ﾠ
extracellulare,	
 ﾠmaggiormente	
 ﾠintaccata	
 ﾠda	
 ﾠdetergenti	
 ﾠionici.	
 ﾠ	
 ﾠ	
 ﾠ
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 ﾠ
Il	
 ﾠ metodo	
 ﾠ TRITDOC	
 ﾠ possiede	
 ﾠ le	
 ﾠ stesse	
 ﾠ caratteristiche	
 ﾠ positive	
 ﾠ del	
 ﾠ metodo	
 ﾠ
precedentemente	
 ﾠ descritto	
 ﾠ tuttavia	
 ﾠ raggiunge	
 ﾠ quantità	
 ﾠ residue	
 ﾠ assolute	
 ﾠ rispetto	
 ﾠ al	
 ﾠ
campione	
 ﾠpiù	
 ﾠbasse	
 ﾠtra	
 ﾠi	
 ﾠquattro	
 ﾠmetodi	
 ﾠanalizzati,	
 ﾠrisultanti	
 ﾠmaggiori	
 ﾠsolo	
 ﾠrispetto	
 ﾠai	
 ﾠ
residui	
 ﾠdi	
 ﾠSDS.	
 ﾠRispetto	
 ﾠDohmen	
 ﾠquesto	
 ﾠmetodo	
 ﾠraggiunge	
 ﾠpiù	
 ﾠdi	
 ﾠun	
 ﾠordine	
 ﾠdi	
 ﾠgrandezza	
 ﾠ
di	
 ﾠmargine	
 ﾠdi	
 ﾠmiglioramento.	
 ﾠ	
 ﾠ
Il	
 ﾠvalore	
 ﾠdi	
 ﾠresiduo	
 ﾠdi	
 ﾠSDS	
 ﾠnon	
 ﾠè	
 ﾠda	
 ﾠconsiderarsi	
 ﾠdel	
 ﾠtutto	
 ﾠaffidabile,	
 ﾠin	
 ﾠquanto	
 ﾠdurante	
 ﾠle	
 ﾠ
analisi	
 ﾠ un	
 ﾠ problema	
 ﾠ al	
 ﾠ detector	
 ﾠ ci	
 ﾠ ha	
 ﾠ costretto	
 ﾠ ad	
 ﾠ utilizzarne	
 ﾠ un	
 ﾠ altro,	
 ﾠ dello	
 ﾠ stesso	
 ﾠ
modello	
 ﾠe	
 ﾠdella	
 ﾠstessa	
 ﾠmarca.	
 ﾠI	
 ﾠdati	
 ﾠattendono	
 ﾠquindi	
 ﾠdi	
 ﾠessere	
 ﾠconfermati.	
 ﾠ	
 ﾠ
È	
 ﾠ necessario	
 ﾠ verificare	
 ﾠ che	
 ﾠ i	
 ﾠ risultati	
 ﾠ siano	
 ﾠ coerenti	
 ﾠ verificando	
 ﾠ un	
 ﾠ campione	
 ﾠ con	
 ﾠ il	
 ﾠ
secondo	
 ﾠdetector.	
 ﾠ
È	
 ﾠ necessario	
 ﾠ inoltre	
 ﾠ puntualizzare	
 ﾠ che	
 ﾠ lo	
 ﾠ studio	
 ﾠ riportato	
 ﾠ analizza,	
 ﾠ come	
 ﾠ quelli	
 ﾠ
precedenti,	
 ﾠ solo	
 ﾠ i	
 ﾠ detergenti	
 ﾠ liberi	
 ﾠ in	
 ﾠ soluzione	
 ﾠ e	
 ﾠ non	
 ﾠ quelli	
 ﾠ eventualmente	
 ﾠ legati	
 ﾠ a	
 ﾠ
frammenti	
 ﾠproteici.	
 ﾠ
In	
 ﾠ conclusione	
 ﾠ possiamo	
 ﾠ notare	
 ﾠ che	
 ﾠ le	
 ﾠ quantità	
 ﾠ residue	
 ﾠ di	
 ﾠ DOC	
 ﾠ all’interno	
 ﾠ dei	
 ﾠ lembi	
 ﾠ
aortici	
 ﾠ decellularizzati	
 ﾠ mediante	
 ﾠ protocolli	
 ﾠ Dohmen	
 ﾠ e	
 ﾠ Haverich	
 ﾠ sono	
 ﾠ intorno	
 ﾠ all’1%,	
 ﾠ
quantità	
 ﾠche	
 ﾠè	
 ﾠstata	
 ﾠdimostrata	
 ﾠessere	
 ﾠtossica.	
 ﾠQuesti	
 ﾠdue	
 ﾠmetodi	
 ﾠdi	
 ﾠdecellularizzazione	
 ﾠ
molto	
 ﾠ diffusi	
 ﾠ quindi	
 ﾠ non	
 ﾠ sono	
 ﾠ affidabili	
 ﾠ dal	
 ﾠ punto	
 ﾠ di	
 ﾠ vista	
 ﾠ dell’eliminazione	
 ﾠ dei	
 ﾠ
detergenti	
 ﾠ utilizzati	
 ﾠ nei	
 ﾠ protocolli.	
 ﾠ Al	
 ﾠ contrario	
 ﾠ le	
 ﾠ quantità	
 ﾠ residue	
 ﾠ di	
 ﾠ COL	
 ﾠ e	
 ﾠ TDOC	
 ﾠ
all’interno	
 ﾠdelle	
 ﾠvalvole	
 ﾠdecellularizzate	
 ﾠcon	
 ﾠmetodi	
 ﾠTRICOL	
 ﾠe	
 ﾠTRITDOC	
 ﾠrisultano	
 ﾠessere	
 ﾠ
in	
 ﾠquantità	
 ﾠnon	
 ﾠtossiche.	
 ﾠ	
 ﾠ
	
 ﾠ
Tabella4.12:	
 ﾠRiassunto	
 ﾠdei	
 ﾠmetodi	
 ﾠdi	
 ﾠdecellularizzazione	
 ﾠ
CAMPIONE	
 ﾠ
Concentrazione	
 ﾠ
detergente	
 ﾠ Tempo	
 ﾠ N°	
 ﾠLavaggi	
 ﾠ Tempo	
 ﾠlavaggi	
 ﾠ
Dohmen	
 ﾠ 1%	
 ﾠDOC	
 ﾠw/v	
 ﾠ 24	
 ﾠore	
 ﾠ 10	
 ﾠ 12	
 ﾠore	
 ﾠciascuno	
 ﾠ
Haverich	
 ﾠ 0.5%	
 ﾠDOC	
 ﾠw/v	
 ﾠ
0.5%	
 ﾠSDS	
 ﾠw/v	
 ﾠ 24	
 ﾠore	
 ﾠ 10	
 ﾠ 12	
 ﾠore	
 ﾠciascuno	
 ﾠ
TRICOL	
 ﾠ 1%	
 ﾠTriton	
 ﾠX-ﾭ‐100	
 ﾠw/v	
 ﾠ
0.43%	
 ﾠCOL	
 ﾠw/v	
 ﾠ
33.5	
 ﾠore	
 ﾠ
16	
 ﾠore	
 ﾠ 2	
 ﾠ 11.5	
 ﾠore	
 ﾠ
24	
 ﾠore	
 ﾠciascuno	
 ﾠ
TRITDOC	
 ﾠ 1%	
 ﾠTriton	
 ﾠX-ﾭ‐100	
 ﾠw/v	
 ﾠ
0.21%	
 ﾠTDOC	
 ﾠw/v	
 ﾠ
33.5	
 ﾠ
16	
 ﾠore	
 ﾠ 2	
 ﾠ 11.5	
 ﾠore	
 ﾠ
24	
 ﾠore	
 ﾠciascuno	
 ﾠ
	
 ﾠ
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CONCLUSIONE	
 ﾠ
	
 ﾠ
I	
 ﾠrecenti	
 ﾠstudi	
 ﾠmostrano	
 ﾠla	
 ﾠnecessità	
 ﾠdi	
 ﾠmigliorare	
 ﾠi	
 ﾠsostituti	
 ﾠvalvolari	
 ﾠbiologici	
 ﾠi	
 ﾠquali,	
 ﾠ
anche	
 ﾠ se	
 ﾠ migliori	
 ﾠ di	
 ﾠ ogni	
 ﾠ altro	
 ﾠ possibile	
 ﾠ sostituto,	
 ﾠ mostrano	
 ﾠ ancora	
 ﾠ parecchi	
 ﾠ punti	
 ﾠ
deboli.	
 ﾠ Le	
 ﾠ cause	
 ﾠ di	
 ﾠ failure	
 ﾠ delle	
 ﾠ bioprotesi	
 ﾠ sono	
 ﾠ molteplici:	
 ﾠ la	
 ﾠ calcificazione,	
 ﾠ la	
 ﾠ
degenerazione	
 ﾠ e	
 ﾠ il	
 ﾠ mancato	
 ﾠ ripopolamento.	
 ﾠ È	
 ﾠ necessario	
 ﾠ approfondire	
 ﾠ tutti	
 ﾠ questi	
 ﾠ
aspetti	
 ﾠal	
 ﾠfine	
 ﾠdi	
 ﾠcreare	
 ﾠuna	
 ﾠvalvola	
 ﾠche	
 ﾠsia	
 ﾠsempre	
 ﾠpiù	
 ﾠsimile	
 ﾠa	
 ﾠquella	
 ﾠideale.	
 ﾠ	
 ﾠ
Questo	
 ﾠ studio	
 ﾠ si	
 ﾠ inserisce	
 ﾠ all’interno	
 ﾠ di	
 ﾠ uno	
 ﾠ più	
 ﾠ ampio	
 ﾠ che	
 ﾠ è	
 ﾠ volto	
 ﾠ a	
 ﾠ determinare	
 ﾠ e	
 ﾠ
sviluppare	
 ﾠmetodi	
 ﾠdi	
 ﾠdecellularizzazione	
 ﾠsempre	
 ﾠpiù	
 ﾠefficienti.	
 ﾠLo	
 ﾠscopo	
 ﾠdi	
 ﾠquesti	
 ﾠè	
 ﾠdi	
 ﾠ
allungare	
 ﾠ la	
 ﾠ durata	
 ﾠ della	
 ﾠ valvola	
 ﾠ così	
 ﾠ come	
 ﾠ evitare	
 ﾠ rigetti,	
 ﾠ infiammazioni	
 ﾠ o	
 ﾠ altre	
 ﾠ
complicazioni.	
 ﾠ La	
 ﾠ quantificazione	
 ﾠ di	
 ﾠ detergenti	
 ﾠ residui	
 ﾠ nella	
 ﾠ matrice	
 ﾠ delle	
 ﾠ valvole	
 ﾠ
sostitutive	
 ﾠ non	
 ﾠ deve	
 ﾠ limitarsi	
 ﾠ semplicemente	
 ﾠ a	
 ﾠ determinare	
 ﾠ il	
 ﾠ protocollo	
 ﾠ di	
 ﾠ
decellularizzazione	
 ﾠ migliore,	
 ﾠ bensì	
 ﾠ deve	
 ﾠ portare	
 ﾠ allo	
 ﾠ sviluppo	
 ﾠ di	
 ﾠ strumenti	
 ﾠ che	
 ﾠ
permettano,	
 ﾠdopo	
 ﾠil	
 ﾠtrattamento	
 ﾠe	
 ﾠl’impianto	
 ﾠdella	
 ﾠvalvola,	
 ﾠdi	
 ﾠverificare	
 ﾠla	
 ﾠstabilità	
 ﾠdella	
 ﾠ
stessa,	
 ﾠl’efficacia	
 ﾠe	
 ﾠla	
 ﾠlongevità.	
 ﾠ	
 ﾠ
Lo	
 ﾠstudio	
 ﾠqui	
 ﾠproposto	
 ﾠinoltre	
 ﾠnon	
 ﾠè	
 ﾠche	
 ﾠuna	
 ﾠpiccola	
 ﾠparte	
 ﾠnello	
 ﾠstudio	
 ﾠdei	
 ﾠdetergenti	
 ﾠ
residui	
 ﾠall’interno	
 ﾠdella	
 ﾠmatrice	
 ﾠdi	
 ﾠvalvole	
 ﾠbiologiche	
 ﾠdecellularizzate,	
 ﾠaltri	
 ﾠprogetti	
 ﾠsono	
 ﾠ
volti	
 ﾠa	
 ﾠdeterminare	
 ﾠquantità	
 ﾠresidue	
 ﾠdi	
 ﾠdetergenti	
 ﾠnon	
 ﾠionici	
 ﾠcome	
 ﾠil	
 ﾠTriton	
 ﾠX-ﾭ‐100,	
 ﾠaltri	
 ﾠ
hanno	
 ﾠlo	
 ﾠscopo	
 ﾠdi	
 ﾠmettere	
 ﾠa	
 ﾠconfronto	
 ﾠl’efficacia	
 ﾠdei	
 ﾠmetodi	
 ﾠqui	
 ﾠanalizzati	
 ﾠsu	
 ﾠtessuti	
 ﾠ
differenti	
 ﾠquali	
 ﾠlembi	
 ﾠpolmonari,	
 ﾠpareti	
 ﾠpolmonari	
 ﾠe	
 ﾠaortiche	
 ﾠporcine	
 ﾠe	
 ﾠbovine.	
 ﾠ	
 ﾠ
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